New findings from the SELECT trial indicate that semaglutide (Wegovy—Novo Nordisk) reduces the risk of major heart complications—heart attacks, strokes, and CV deaths—by 20%. The 5-year randomized trial of approximately 17,500 patients is the first to demonstrate that an obesity drug can have long-term CV benefits.